Zsofia K Stadler

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
  2. ncbi Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
  3. ncbi Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
  4. ncbi An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
  5. ncbi BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
  6. ncbi The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Colorectal Cancer 11:304-8. 2012
  7. ncbi Genome-wide association studies of cancer: principles and potential utility
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:629-37. 2010
  8. ncbi Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply?
    Clare D'Arcy
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 35:1743-8. 2011
  9. ncbi Diagnosing hereditary colorectal cancer
    David J Gallagher
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 9:205-11. 2010
  10. ncbi Genetic testing in gastrointestinal cancers: a case-based approach
    Kasmintan Schrader
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 26:433-6, 438, 444-6 passim. 2012

Collaborators

Detail Information

Publications14

  1. ncbi Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
    ..Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown...
  2. ncbi Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:493-9. 2012
    ..Breast-pancreas cancer families with BRCA1 mutations have also been observed. The influence of a family history (FH) of PC on BRCA mutation prevalence in patients with breast cancer (BC) is unknown...
  3. ncbi Genome-wide association studies of cancer
    Zsofia K Stadler
    Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
    J Clin Oncol 28:4255-67. 2010
    ..To date, however, the clinical utility of GWAS-derived risk markers remains limited...
  4. ncbi An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions
    Maeve A Lowery
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 16:1397-402. 2011
    ....
  5. ncbi BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
    ..Analysis of a tumor specimen indicates loss of heterozygosity. These results support the conclusion that BRCA1 331G > A (R71K) is a deleterious mutation...
  6. ncbi The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Colorectal Cancer 11:304-8. 2012
    ..The purpose of this study was to report the prevalence of TC and benign thyroid disease in patients with FAP...
  7. ncbi Genome-wide association studies of cancer: principles and potential utility
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:629-37. 2010
    ....
  8. ncbi Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply?
    Clare D'Arcy
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 35:1743-8. 2011
    ....
  9. ncbi Diagnosing hereditary colorectal cancer
    David J Gallagher
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 9:205-11. 2010
    ..While these associations have helped to identify potentially important pathways in CRC carcinogenesis, at the current time, the clinical use of such genetic risk variants in colon cancer risk stratification remains limited...
  10. ncbi Genetic testing in gastrointestinal cancers: a case-based approach
    Kasmintan Schrader
    Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncology (Williston Park) 26:433-6, 438, 444-6 passim. 2012
    ..In this article, we use a case-based approach to focus on the hereditary aspects of the most common GI cancers, including pancreatic, gastric, and colon cancer...
  11. ncbi Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...
  12. ncbi Rare de novo germline copy-number variation in testicular cancer
    Zsofia K Stadler
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Hum Genet 91:379-83. 2012
    ....
  13. ncbi Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection
    Emily Steinhagen
    Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 214:61-7. 2012
    ..Our study describes the impact of routine immunohistochemistry (IHC) analysis of tumor tissue for loss of MMR protein expression in early age-of-onset CRC patients undergoing resection...
  14. ncbi Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families
    Zsofia K Stadler
    Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    Breast Cancer Res Treat 123:581-5. 2010
    ..Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim...